{"id":70349,"date":"2026-07-21T19:09:53","date_gmt":"2026-07-21T11:09:53","guid":{"rendered":"https:\/\/flcube.com\/?p=70349"},"modified":"2026-07-21T19:09:54","modified_gmt":"2026-07-21T11:09:54","slug":"jacobio-pharmaceuticals-jab-8263-bet-inhibitor-proposed-for-nmpas-rare-disease-caring-program-for-myelofibrosis-treatment","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=70349","title":{"rendered":"Jacobio Pharmaceuticals’ JAB-8263 BET Inhibitor Proposed for NMPA’s Rare Disease “Caring Program” for Myelofibrosis Treatment"},"content":{"rendered":"\n

The Center for Drug Evaluation (CDE)<\/strong> of China’s National Medical Products Administration (NMPA)<\/strong> announced that Jacobio Pharmaceuticals<\/strong> (HKG: 1167<\/a>) has been proposed for inclusion in the “Caring Program – Extension”<\/strong> pilot initiative for its JAB-8263 tablets<\/strong>, a BET inhibitor<\/strong> developed for the treatment of myelofibrosis<\/strong>. The designation, granted under the “Pilot Program for Encouraging the Development of Innovative Drugs for Rare Diseases”<\/strong>, provides accelerated regulatory pathways and enhanced support for promising therapies addressing unmet medical needs in rare disease populations.<\/p>\n\n\n\n

Regulatory Designation & Program Benefits<\/h2>\n\n\n\n
Component<\/th>Detail<\/th><\/tr><\/thead>
Regulatory Body<\/strong><\/td>CDE\/NMPA (China)<\/td><\/tr>
Program Name<\/strong><\/td>“Caring Program – Extension”<\/td><\/tr>
Drug Candidate<\/strong><\/td>JAB-8263 tablets<\/td><\/tr>
Developer<\/strong><\/td>Jacobio Pharmaceuticals (HKG: 1167)<\/td><\/tr>
Therapeutic Area<\/strong><\/td>Myelofibrosis (rare hematological malignancy)<\/td><\/tr>
Drug Class<\/strong><\/td>BET inhibitor<\/td><\/tr>
Program Objective<\/strong><\/td>Accelerate development of innovative rare disease therapies<\/td><\/tr>
Announcement Date<\/strong><\/td>July 20, 2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Clinical Development Progress<\/h2>\n\n\n\n